Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, there were significant differences in interleukin (IL)-6 and tumor necrosis (TNF)-α concentrations at 24 h after hepatectomy between the two groups, and mean arterial pressure, heart rate, and the bispectral index were also significantly lower in D group than in C group (p < .05).
|
31669050 |
2020 |
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Functional enrichment analyses suggested that the upregulated genes were markedly enriched in inflammation-related biological processes, as well as in the tumor necrosis factor (TNF) signaling pathway, cytokine-cytokine receptor interactions, complement and coagulation cascades, and in the chemokine signaling pathway.
|
31044753 |
2020 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Additionally, the majority of DEGs were mainly enriched in NF-kappa β (NF-kβ) signaling pathway and tumor necrosis factor (TNF) signaling pathway.
|
31277141 |
2019 |
Tumor necrosis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Results showed that both PR and PS nanofibers have the ability to induce chondrogenesis of MSCs and accelerate the regeneration of injured cartilage surface, probably via the suppression of Tumor necrosis factor (TNF) signaling pathway as evidenced by microarray profiles.
|
30890231 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pathway analysis suggests that tumor necrosis factor (TNF) signaling pathway, NOD-like receptor pathway, and cytokine-cytokine receptor interaction may be involved in ALI.
|
30979832 |
2019 |
Tumor necrosis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Analytes of the tumor necrosis factor (TNF) signaling pathway (KEGG ID:4668) in the CSF and plasma best correlated with CSF t-tau and p-tau levels, and analytes of the complement and coagulation pathway (KEGG ID:4610) best correlated with CSF Aβ42 levels.
|
31353852 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In particular, genes involved in tumour necrosis factor (TNF) signalling were significantly deregulated in MS cases compared with controls.
|
31810488 |
2019 |
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Functional analysis of DEGs obtained that inflammatory responses, immune responses, and positive regulation of apoptosis, tumor necrosis factor (TNF) signaling pathway, and osteoclast differentiation may be involved in the pathogenesis of OA.
|
30317616 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Lipid metabolism, cell differentiation and proliferation, peroxisome proliferator-activated receptor (PPAR), wingless-type MMTV integration site (Wnt), tumor necrosis factor (TNF) signaling, and steroid biosynthesis were significant at days 2, 4, and 8 compared to day 0 (adjusted <i>p</i> < 0.05).
|
31331100 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
KEGG pathway analysis revealed a significant enrichment of genes associated with the tumor necrosis factor (TNF) signaling pathway.
|
31653960 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Individuals with periodontitis have increased systemic levels of acute phase proteins, plasma antibody levels, coagulation factor, total white blood cell count, neutrophils, C reactive protein (CRP), and cytokines such as INF- gamma (Interferon gamma), TNF-α (Tumor necrosis Factor- Alpha), IL (Interleukin)-1β, IL-2 and IL-6.
|
30384973 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Upregulated DEGs were involved in Cell adhesion molecules (ICAM1, intercellular adhesion molecule 1) and tumor necrosis factor (TNF) signaling pathway (FOS, FBJ osteosarcoma oncogene; ICAM1), while downregulated DEGs participated in PPAR signaling pathway (PPARG, peroxisome proliferator-activated receptor gamma).
|
31149396 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
GO and KEGG analyses revealed roles for the potential mRNA targets of MIR137HG in epithelial cell differentiation and the peroxisome proliferator-activated receptor (PPAR) and tumor necrosis factor (TNF) signaling pathways.
|
31308745 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Selective inhibition of tumor necrosis factor (TNF) signaling through the proinflammatory axis of TNF-receptor 1 (TNFR1) while leaving pro-survival and regeneration-promoting signals via TNFR2 unaffected is a promising strategy to circumvent limitations of complete inhibition of TNF action by the approved anti-TNF drugs.
|
30252601 |
2019 |
Tumor necrosis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Our results revealed that treatment of POCD rats with TPM could suppress neuronal apoptosis in the hippocampus tissues, and the neuroprotective effects of TPM may relate with the regulation of tumor necrosis factor (TNF) signaling pathway.
|
31758388 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hypersensitivity of autophagy gene-deficient cells to IFNγ was mediated by tumor necrosis factor (TNF) signaling via receptor interacting protein kinase 1 (RIPK1)- and caspase 8-mediated cell death.
|
31346084 |
2019 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
L19-TNFα/L19-IL2 combination therapy eradicated tumors in J558L myeloma BALB/c mice likely via TNFα-induced tumor necrosis and L19-TNFα/L19-IL2-mediated local cellular immune reactions.
|
29327244 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) signalling is mediated via two receptors, TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2), which work antithetically to balance CNS immune responses involved in autoimmune diseases such as multiple sclerosis.
|
30206422 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that these DEGs were mainly associated with metabolic pathways, the peroxisome proliferator-activated receptor (PPAR) signaling pathway, regulation of lipolysis in adipocytes, the tumor necrosis factor (TNF) signaling pathway, and the FoxO signaling pathway.
|
30424473 |
2018 |
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
This study used an in vitro model to explore the expression and function of tumor necrosis factor (TNF) signaling pathway in bupivacaine-induced apoptotic injury in spinal cord dorsal root ganglia (DRG).
|
29802833 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Consecutive CD patients with intestinal strictures that initiated treatment with anti-tumor necrosis alpha (anti-TNF) between June 2012 and April 2017 with MRE adjacent to treatment onset were retrospectively collected.
|
29779158 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We have previously shown that progesterone inhibits basal and Tumor Necrosis Factor (TNF) α-induced apoptosis in an explant model of human fetal membranes.
|
29463188 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The concentrations of TNF-α (Tumor Necrosis Factor-α), IL-1β (Interleukin-1β), IL-6 (Interleukin-6) and PGE-2 (Prostaglandin E2) were evaluated using ELISA.
|
29501766 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Contribution of the TNF-α (Tumor Necrosis Factor-α)-TNF-Rp55 (Tumor Necrosis Factor Receptor p55) Axis in the Resolution of Venous Thrombus.
|
30354252 |
2018 |
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In tumour necrosis factor (TNF) signalling, linear (also known as M1) ubiquitin enables full gene activation and prevents cell death.
|
30420664 |
2018 |